title: Gentamicin clearance during continuous arteriovenous hemodiafiltration.
abstract: OBJECTIVE
  To investigate the feasibility of predicting gentamicin dosing requirements during continuous arteriovenous hemodiafiltration (CAVHD).
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  General intensive therapy unit in a university teaching hospital.
  
  
  METHODS
  Five adult patients with acute renal failure in whom both dialytic and gentamicin therapy were indicated.
  
  
  RESULTS
  CAVHD clearance and total body clearance of gentamicin were estimated from serial gentamicin concentrations in the blood and the combined ultrafiltrate and dialysate. Results (mean +/- SD) were: CAVHD clearance of gentamicin 5.2 +/- 1.8 mL/min; total body clearance of gentamicin 20.5 +/- 6.9 mL/min; ultrafiltrate flow rate 7.0 +/- 2.4 mL/min (420 +/- 146 mL/hr). CAVHD clearance of gentamicin was small and represented approximately 25% of total body clearance of gentamicin, although significant interpatient variation existed in these measurements and in the proportion of total gentamicin clearance attributable to CAVHD. CAVHD clearance of gentamicin was related to the ultrafiltrate flow rate (r2 = .81).
  
  
  CONCLUSIONS
  CAVHD clearance of gentamicin may be predicted for variable ultrafiltrate flow rates. However, due to its minor and variable contribution to total body clearance of gentamicin, prediction of gentamicin dosing requirements based on estimates of CAVHD clearance of gentamicin would be precluded and close monitoring of circulating gentamicin concentrations during CAVHD is necessary.
authors.affiliation: Intensive Therapy Unit, Royal North Shore Hospital, Sydney, Australia.
authors.forename: D
authors.initials: D
authors.lastname: Ernest
authors.forename: D J
authors.initials: DJ
authors.lastname: Cutler
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D005260:Female; D005544:Forecasting / Q000379:methods*; D005839:Gentamicins / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006440:Hemofiltration / Q000379:methods; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D005839:Gentamicins